Connect your AI

Denali Therapeutics Inc. DNLI Total Equity

Total Equity at other companies

Eli LillyLLY

$31.2B+97.9%

Regeneron PharmaceuticalsREGN

$31.42B+6.9%

Viking TherapeuticsVKTX

$501.92M-40.7%

Acadia PharmaceuticalsACAD

$1.25B+63.1%

BridgeBio PharmaBBIO

-$2.28B-38.2%

BiogenBIIB

——

Other financials

Income statement

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total assets$1.3B-0.4%

Cash flow

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

Market cap$3.7B+54.2%

Enterprise value$3.35B+37.1%

Profitability

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Denali Therapeutics Inc.'s total equity?: Denali Therapeutics Inc. (DNLI) reported total equity of $926.1M in Q1 2026.
How has Denali Therapeutics Inc.'s total equity changed year-over-year?: Denali Therapeutics Inc.'s total equity decreased by 17.5% year-over-year, from $1.12B to $926.1M.
What is the long-term trend for Denali Therapeutics Inc.'s total equity?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s total equity has grown at a -2.5% compound annual growth rate (CAGR), from $1.15B to $1.01B.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.